Executive Briefing presented by the Center for Anti-Infective Agents (CEFAIA)

4th Antibacterial Market Executive Briefing on November 14th, 14:00 to 18:00, in Munich, Germany.

Challenges in the antibacterial market
Resistance demands action

Information

7th Annual Anti-Infectives Partnering & Deal-Making Summit, Oct 7-8, 2010 in Boston, MA
U. Theuretzbacher: The Global Need for New Antibiotics – International Actions and Implications for Antibacterial Drug Development

2nd Anti-Infectives Summit
September 27 - 29, 2010, San Francisco, CA

U. Theuretzbacher: Multi-Drug Resistance As A Driver In The Development Of New Drugs

Activities of Ursula Theuretzbacher during the ICAAC 2010 in Boston, MA:

• Symposium “Novel Antibacterial Agents by Licensing: what Big Pharma wants and what Small Biotech can offer"
  U. Theuretzbacher: "What’s on the shelf: The biotech pipeline of novel antibiotics". Abstract
  Sept. 12, 4:00:00 - 6:00 PM, room 258A
• Chair: Symposium "Penetration of Anti-Infective Agents"
  Sept. 15, 8:30:00 - 10:30:00 AM, 210A
• ISAP Workshops, Boston, MA
  Sept. 11, 9:00 am - 4:30 pm, Westin Boston Waterfront Hotel:
  - Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents
  - Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents
• ISAP Post-ICAAC Symposium, Boston, MA
  September 15th, 2:00-6:00 pm, Westin Boston Waterfront Hotel
  Program:PK/PD in special sites of infection - TB drugs
  - Brief introduction to M. tuberculosis-infection (U. Theuretzbacher
  - Studying PK/PD of TB drugs - A daunting challenge (C. Peloquin)
  - Young investigator presentations (PK/PD of TB drugs and general PK/PD): 10 min presentations

16th Symposium on Infections in the Immunocompromised Host
27- 30 June 2010, Budapest, Hungary

Ursula Theuretzbacher: Antimicrobial PK/PD Issues for Cancer Patients

Activities of Ursula Theuretzbacher during the ECCMID 2010 in Vienna, Austria

• ISAP/EPASG workshop
• Inaugural meeting of EPASG
• Poster presentation at European Network Corner
• Official symposium at ECCMID:
  Role of pharmacokinetics in early stages of antimicrobial development
• Post-ECCMID ISAP/EPASG symposium

April 2010

ISAP/EPASG joint symposium

Post-ECCMID symposium in Vienna
April 13, 2010, 15.00-18.00
Le Méridien, Opernring13, 1010 Vienna, Austria

15.00-15.10 Welcome and Introduction
U. Theuretzbacher, Markus Müller

15.10-15.35 PK/PD and prevention of resistance
A. MacGowan

15.35-16.05 Protein binding
U. Theuretzbacher: planned publication
H. Derendorf: Late breaker results

16.05-16.30 Break

16.30-17.50 PK/PD of potentiator combinations
M. Dudley: PK/PD aspects of bacterial efflux–pump inhibitors
M. Zeitlinger: PK/PD aspects of eucaryotic efflux–pumps and inhibitors
G. Drusano: PK/PD of new beta-lactamase inhibitor combinations
J. Mouton: PK/PD challenges in the development of ß-lactamase inhibitor combinations

17.55-18.00 Conclusion
A. MacGowan (ISAP president elect)

Planning Committee:
U. Theuretzbacher, PhDCenter for Anti-Infective Agents, Vienna, Austria
M. Zeitlinger, MDMedical Univ. Vienna, Austria
M. Müller, MDMedical Univ. Vienna, Austria
Faculty:
H. Derendorf, PhD; Univ. of Florida, Gainesville, FL. USA
G. Drusano, MD; Ordway Research, Albany, NY, USA
M. Dudley, Pharm.D.; Mpex Pharmaceuticals, San Diego, CA, USA
A. MacGowan, MD; Bristol Center for Antimicrobial Research, Bristol, UK
J. Mouton, MD, PhD; Radboud University Nijmegen Medical Centre, Nijmegen, NL
M. Müller, MD; Medical Univ. Vienna, Vienna, Austria
U. Theuretzbacher, PhD; Center for Anti-Infective Agents, Vienna, Austria
M. Zeitlinger, MD; Medical Univ. Vienna, Vienna, Austria

April 2010

20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Official Symposium
Tuesday, April 13, 2010
13:30 - 15:30, Lecture Hall F1

Challenges and solutions for determining pharmacokinetics of antimicrobials in the human body
Chair: A. Novelli (Florence, IT)
G. Drusano (Albany, US)

13:30 - 14:00 Role of pharmacokinetics in early stages of antimicrobial development
U. Theuretzbacher (Vienna, AT)

14:00 - 14:30 PK modelling: obtaining PK profiles despite sparse sampling
J.B. Bulitta, A. Bingölbali, C. Landersdorfer (Albany, US)

14:30 - 15:00 Microdialysis – applications, pitfalls and future aspects of a powerful technique
C. Kloft (Halle, DE)

15:00 - 15:30 Imaging and microdosing – how do they fit for antimicrobial agents?
O. Langer (Vienna, AT)

April 2010

20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

10-13 April 2010, Vienna, Austria

Educational workshop arranged with the International Society of Anti-Infective Pharmacology (ISAP) and ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Saturday, April 10, 2010, 09:00 - 13:00
Hall C

Optimizing treatment using a pharmacodynamic approach: an interactive workshop using clinical cases
Chair: J. Mouton (Nijmegen, NL), U. Theuretzbacher (Vienna, AT)

- Dosing and duration of treatment of aminoglycoside therapy
W. Craig (Madison, US)
- Choosing an antimicrobial for CAP
U. Theuretzbacher (Vienna, AT)
- Continuous infusion of beta-lactams
J. Mouton (Nijmegen, NL)
- Treatment with glycopeptides: intermittent dosing or continuous infusion?
H. Derendorf (Gainesville, US)
- Dose adjustments in patients with an impaired renal function
H. Derendorf (Gainesville, US)
- Combination treatment
J. Mouton (Nijmegen, NL)

November 2009

Executive Briefing presented by the Center for Anti-Infective Agents (CEFAIA)

Mark your calendar as the dates have been set for the 3rd Antibacterial Market Executive Briefing. Join us on November 1st, 14:00 to 18:00, in Vienna, Austria.

Challenges in the antibacterial market
Moving out of survival mode

Information and registration

Post-ICAAC symposium in San Francisco organized by ISAP

Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), SAn Francisco 2009, USA

Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

16-19th May 2009, Helsinki, Finnland

Educational workshop:
Pharmacokinetics and pharmacodynamics of anti-infective agents

6th Anti-Infectives Partnering & Deal-Making Summit
March 5-6, 2009, Boston, MA

Diagnostics Team Up with Narrow-Spectrum Antibiotics: Synergistic Business Opportunities and Evolving Trends

The development of narrow-spectrum or single pathogen–only antibiotics is increasingly seen as attractive niche market opportunities. Resistance challenges, antibiotic control programs in hospitals, escalating health care costs, long development time lines, regulatory environment challenges, and dry pipelines, power the trend to more targeted therapies. Driven by the principles of personalized medicine, the hospital point-of care rapid diagnostic market promises dramatic market expansion via improved and rapid tests that are reliable and easy to integrate into hospital routine. Diagnostic-therapeutic co-development and early partnerships will be important drivers for targeting the clinical trial population and accessing markets more rapidly and efficiently. This overview discusses
• Existing examples for diagnostic-therapeutic partnerships
• Strategies for the clinical development phase
• Regulatory opportunities and pitfalls
• Synergistic strategies for diagnostic and drug development companies in the market

Re-emerging Infectious Diseases conference
11th -12th December 2008, London UK

Cultural implications for antibacterial drug development and usage
• Differences in general perception of medicine and antibiotic usage in US vs EU
• Medical need – everywhere the same?
• Cultural implications regarding drug development and commercialization strategies in US vs EU

Executive Briefing

Optimising partnering strategies in the anti-infectives market
The comeback of the antibacterial business

November 16th, 14:00 to 18:00
in Mannheim, Germany

2nd World Conference on Magic Bullets (Ehrlich II) in Nürnberg, Germany, October 3 - 5, 2008

Oral presentation:
Evaluating our performance: Tissue penetration paradigm shift
Abstract

PK/PD workshop

18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID):

• Educational workshop:
  Pharmacokinetics and pharmacodynamics of anti-infective agents
• Meet-the-Expert session:
  What is the role of PK/PD in the management of fungal infections? How to handle in the everyday life?
• Symposium:
  Antibiotic stewardship in the ICU: today and tomorrow

11th International Symposium Current Topics in Infectious Diseases
Jan 29th-Feb 1st, Grindelwald, Switzerland

Antibiotics: what's new and what's in the pipeline?"

2nd Annual APUA World Congress, Oct. 29-30, 2007, Boston, MA
Program

SYMPOSIUM & ROUNDTABLE: Oct 28th
Future Strategies in Drug Development and Prescribing
Co-Chairs: Ian Gould, MB, FRCPE; Christopher Spivey, MBA
Co-sponsored by the International Society for Chemotherapy (ISC) and the Alliance for the Prudent Use of Antibiotics (APUA)

• Steven J. Projan, PhD, Biological Technologies, Wyeth Research — “How can we control antibiotic resistance when we don’t understand it?”
• Ian Gould, MB, FRCPE, Consultant Microbiologist, Aberdeen Royal Infirmary, UK — “Unintended consequences of prescribing policies”
• Dominique L. Monnet, PharmD, PhD, Statens Serum Institut, Denmark — “Encouraging development of new antibacterials while preserving the old”
• Robert C. Moellering, MD, Beth Israel Deaconess Medical Center, Harvard Medical School — “New concepts of anti-infective therapy” — Tentative
• Ursula Theuretzbacher, PhD, Center for Anti-Infective Agents — “Antimicrobials in the future”
Panel Discussion

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago 2007, USA

Presentation at FDA in Washington DC, Division of Pharmaceutical Evaluation III, Oct 22nd, 2007

The Influence of Tissue Distribution and Protein Binding on Resistance.

Abstract

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago 2007, USA

Executive Briefing following the smi-conference Superbugs & Superdrugs in London, 23rd to 24th April 2007

This Executive Briefing will explore the biggest issues in antibacterial resistance looking in-depth at the current market and forward 10 years into the future. Attendees will explore the resistance problem and examine the current R&D pipeline.

Poster at the ISC (International Society of Chemoptherapy) / ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Networking Corner during the ECCMID, March 30- April 2, 2007

Symposium: ISC (International Society of Chemoptherapy) / ESCMID (European Society of Clinical Microbiology and Infectious Diseases), Munich, March 31, 2007, Germany

ISC Working Group on Future Antimicrobials and ESGAP (ESCMID Study Group on Antibiotic Policies)
Reconciling the goals of antibiotic policy and drug development.
Chair: J-C. Pechère (Geneva, CH)
I.C. Gyssens (Rotterdam, NL)

Faculty:
U. Theuretzbacher (Vienna, AT)
R.C. Moellering (Boston, US)
D.L. Monnet (Copenhagen, DK)
M.M. Dudley (San Diego, US)
W.A. Craig (Madison, US)
I. Gould (Aberdeen, UK)

Educational Workshop
in cooperation with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), organized by ISAP (International Society of Anti-Infective Pharmacology), Munich, March 31, 2007, Germany

ISAP (International Society of Anti-Infective Pharmacology) Symposium in Munich, March 30th, 2007, Munich, Eden Hotel Wolff

11:00 am -12:00 pm
Introduction into PK/PD of anti-infectives - the essentials in 60 minutes
Hartmut Derendorf, Ursula Theuretzbacher

1:50 pm- 2:20 pm
Emergence of Resistance in Bacteria: Drug Penetration matters
Ursula Theuretzbacher

4th Anti-Infectives Partnering & Deal-Making Summit - Jan. 25-26, 2007, San Francisco, USA

8th European Congress of Chemotherapy and Infection, Budapest 2006, Hungary.
Symosium PK/PD and resistance

Abstract

Bio2Device Group Meeting, Oct 3rd 2006, Sunnyvale, CA, USA
Bad Bugs, No Drugs - A View from Both Industry and the Marketplace
Abstract

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco 2006, USA

Introduction to PK/PD
H. Derendorf, PhD
Department of Pharmaceutics, University of Florida, Gainsville, FL

PK/PD indices
J. Mouton, MD, PhD
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

Protein binding, tissue distribution
U. Theuretzbacher
Center for Anti-Infective Agents, Vienna, Austria

In vitro models
I. Odenholt, MD
Departement of Infectious Diseases, Malmö University Hospital, Malmö, Sweden

Animal models
W.A. Craig,
Division of Infectious Diseases, University of Wisconsin, Madison, WI

In vitro resistance
O. Cars,
Division of Infectious Diseases, University Hospital, Uppsala, Sweden

Annual Conference on Antimicrobial Resistance - June 26-28, Bethesda, USA

Abstract

Educational Workshop in cooperation with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), organized by ISAP (International Society of Anti-Infective Pharmacology), Nice 2006, France

3rd Anti-Infectives Partnering & Deal-Making Summit - Jan. 26-27, San Diego, USA

Abstract

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington 2005, USA

European Congress of Chemotherapy and Infection (ECC), Florence

Abstract

Anti-Infectives Partnering & Deal-Making Summit,
March 7-8, 2005, Philadelphia, PA, USA

Abstract

Anti-Infectives Partnering & Deal-Making Summit,
May 17-18, 2004, San Diego, CA, USA

Abstract